A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma

Ocular Hypertension Clinical Trial

Official title:

A Three Part, First-in-human, Randomized, Double-masked, Placebo-Controlled, Safety, Tolerability and Early Efficacy Study of MGV354 in Healthy Subjects and in Patients With Ocular Hypertension or Glaucoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02743780
• Other study ID #: MGV354-2201
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: March 2, 2016
• Est. completion date: September 20, 2016

Study information

• Verified date: August 2017
• Source: Alcon Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).

Description:

Part 1 will evaluate the safety and tolerability of single ascending doses of MGV354 compared to placebo in healthy male and female subjects. Part 2 will evaluate the safety and tolerability of MGV354 in a multiple ascending dose design (two highest tolerated doses from Part 1) compared to placebo when administered for 7 days to patients with ocular hypertension or glaucoma. Part 3 will explore the safety, tolerability and efficacy of a single dose level of MGV354 (maximum tolerated dose) compared to placebo when administered for 7 days in patients with ocular hypertension or glaucoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 191
• Est. completion date: September 20, 2016
• Est. primary completion date: September 20, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Documented informed consent.

• Part 1: 18 to 70 years of age;

• Parts 2 and 3: 18 years of age or older;

• Able to communicate well with the investigator and understand and comply with the requirements of the study;

• Body Mass Index (BMI) between 18 and 39;

• In case of contact lens wear, willing to remove lenses 30 minutes before the first assessment until the end of the study. Corrective spectacles may be worn as needed.

• Sitting vital signs (systolic and diastolic blood pressure and pulse rate) within normal ranges as specified in the protocol;

• Part 1 (Healthy Volunteers): In good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.

• Parts 2 and 3 (Patients): Diagnosed with open-angle glaucoma or confirmed ocular hypertension; mean IOP measurements in at least one eye after washout as specified in the protocol

• Other protocol-specified inclusion criteria may apply.

Exclusion criteria:

• History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes;

• History of or current presence of clinically significant ECG abnormalities or arrhythmias;

• History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical or breast cancer), treated or untreated, within the past 5 years;

• Known clinical history of heart failure, myocardial infarction, or stroke;

• Exposure during the four weeks preceding the Screening visit to any topical, inhaled, or systemic corticosteroids;

• Angle grade less than Grade 2 in either eye;

• Any abnormality, including corneal thickness > 620 microns, preventing reliable applanation tonometry;

• Pregnant or lactating women and women of child-bearing potential;

• Sexually active males must agree to use a condom during intercourse while taking drug and for 6 days after stopping MGV354 medication and should not father a child in this period;

• Positive HIV, Hepatitis B Ag or Hepatitis C Ab test result at Screening;

• Abnormal liver function tests;

• History or presence of impaired renal function;

• Part 1 (Healthy Volunteers): Use of any NEW prescription drugs or herbal supplements within four (4) weeks prior to initial dosing, and/or NEW over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing.

• Parts 2 and 3 (Patients): Patients with related disease condition(s) including any form of glaucoma other than open-angle glaucoma and pseudoexfoliation and/or pigment dispersion components; patients who cannot safely discontinue use of all topical ocular and/or systemic IOP-lowering medication according to protocol-specified Washout Schedule; patients with ocular diseases or conditions as specified in the protocol; patients taking certain medications as specified in the protocol;

• Other protocol-specified exclusion criteria may apply.

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Hypertension
• Ocular Hypertension
• Open-Angle Glaucoma

Intervention

Drug:
• MGV354 ophthalmic suspension

• MGV354 placebo
Inactive ingredients used as placebo comparator

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Alcon Research	Novartis Institute for BioMedical Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 3: Change in Diurnal IOP (Averaged Over 8 AM, 10 AM, Noon, 4 PM, and 8 PM) From Baseline to Day 8	IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Diurnal IOP was defined as the average of the five time points measured (8 AM, 10 AM, noon, 4 PM, and 8 PM). Baseline diurnal IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8 and averaging the available changes. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.	Baseline, Day 8
Primary	Part 3: Change in IOP From Baseline to Day 8 at 8 AM, 10 AM, Noon, 4 PM, and 8 PM	IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Baseline IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.	Baseline, Day 8
Secondary	Part 3: Change From Baseline in IOP at 36 Hours and 48 Hours Post Day 7 Administration	IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and reported in mmHg. Baseline IOP was the average of IOP measurements obtained at the 2 eligibility visits. Change from baseline was calculated by taking the change at each time point from baseline to Day 8 and averaging the available changes. A more negative change from baseline indicates a greater improvement, i.e., a reduction of IOP. Only one eye (study eye) contributed to the analysis.	Baseline, up to Day 9
Secondary	Part 1: Maximum Observed Concentration [Cmax (ng/mL)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. Cmax is reported as mass/volume.	Pre-dose, .5, 2, 4, 6, 12, 24, 48, 72, 96, 120 hours post-dose, and Day 7 post-dose
Secondary	Part 1: Time to Reach Maximum Concentration [Tmax (h)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point.	Pre-dose, .5, 2, 4, 6, 12, 24, 48, 72, 96, 120 hours post-dose, and Day 7 post-dose
Secondary	Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUClast (ng*h/mL)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. AUClast is reported as mass*time/volume.	Pre-dose, .5, 2, 4, 6, 12, 24, 48, 72, 96, 120 hours post-dose, and Day 7 post-dose
Secondary	Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to 120 Hours Post Dose [AUC0-120 (ng*h/mL)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was to be collected at each time point.	Pre-dose to 120 hours post-dose
Secondary	Part 1: Area Under the Concentration-time Curve From 0 to Infinity [AUCinf (ng*h/mL)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was to be collected at each time point.	Pre-dose to 120 hours post-dose
Secondary	Part 1: Terminal Elimination Half-life [t1/2 (h)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was to be collected at each time point.	Pre-dose to 120 hours post-dose
Secondary	Part 2: Maximum Observed Concentration [Cmax (ng/mL)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. Cmax is reported as mass/volume.	Up to Day 7
Secondary	Part 2: Time to Reach Maximum Concentration [Tmax (h)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point.	Up to Day 7
Secondary	Part 2: Area Under the Concentration-time Curve From 0 to the End of the Dosing Interval Tau [AUCtau (ng*h/mL)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. AUCtau is reported as mass*time/volume.	Up to Day 7
Secondary	Part 2: Accumulation Ratio (Racc)	Accumulation Ratio was derived using Cmax on Day 7 versus Cmax on Day 1. Approximately 2 mL of venous blood was collected at each time point.	Day 7
Secondary	Part 3: Observed Concentration at 12 Hours Following Drug Administration [C12 (ng/mL)]	Based on plasma samples collected at pre-determined nominal time points, dependent on observed concentrations. Approximately 2 mL of venous blood was collected at each time point. C12 is reported as mass/volume.	Up to Day 8

External Links

•   Results from the Novartis Clinical Trial Results Website